Intraoperative Mitomycin-C versus Bevacizumab on Success Rate of Phacotrabeculectomy

Panahibazaz Panahibazaz, Zamani M Zamani M, Sharifipoor F Sharifipoor F, Khoshnod Khoshnod, Latifi M Latifi M


Background and objective: : To compare the success rate of mitomycin-C Versus bevacizumab for prevention of bleb failure following phacotrabeculectomy.

Material Methods: In this study 74 eyes of 69 patients with uncontrolled IOP, progressive visual field loss and cataract were randomized in two groups. In the first group, after conjunctival peritomy at the sclera flap site, sponge pats soaked in mitomycin C with concentration of 0.25mg/ml were applied for 3 minutes. In the second group, bevacizumab with concentration of 1.25mg/0.5ml was injected adjacent to the bleb at the end of surgery.

Results: Seventy four eyes of 69 patients including 41 men and 28 women with mean age of 66.92±9.8 years and 64.57±8.8 years in either study group respectively were included. Data, collected from 6 to 12 months after surgery, were analyzed. Mean intraocular pressure in the bevacizumab group was significantly higher than the MMC group (15.91±4.9 mmHg vs 12.76±3.1 mmHg, P= 0.001) at 6 months and (15.76±3.26 mmHg vs 13±2.4 mmHg, P= 0.003) at the end of 12 months. Bleb characteristics including extension, elevation and vascularity showed no significant difference between two groups. (P values 0.94, 0.93, 0.41 after 6 months, and 0.56, 0.58, 0.89 after 1 year of follow up respectively). One eye in the second group underwent trabeculectomy because of uncontrolled IOP despite using 3 antiglaucoma medications. One eye in each group underwent bleb revision due to failing bleb. No side effects related to the medications were noted in any of the two groups.

Conclusion: Mitomycin C is more effective than bevacizumab for IOP control after phacotrabeculectomy; however, there is no difference between the two agents in terms of bleb characteristics and side effects.

Full Text:



Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol 2002;86:238-242.

Vass C, Menapace R. Surgical strategies in patients with combined cataract and glaucoma. Curr Opin

Ophthalmol 2004;15:61-66.

Carins JE.Trabeculectomy.preliminary report of a new method. Am J Ophthalmol 1968;66:673-679.

Hitchings RA, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery.

Trans Ophthalmol Soc U K 1983;103:84-88.

Khaw PT, Occleston NL, Schultz G, Grierson I, Sherwood MB, Larkin G. Activation and suppression

of fibroblast function. Eye (Lond) 1994;8:188-195.

Honjo M, Tanihara H, Kameda T, Kawaji T, Yoshimura N, Araie M. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2007;48:5549-5557.

Jacobi J, Tam BY, Sundram U, Von Degenfeldn G, M Blau H, J Kuo C et al. Discordant effects of a soluble VEGF receptor on wound healing and angiogenesis. Gene Ther 2004;11:302-309.

Watanabe J, Sawaguchi S, Fukuchi T, Abe H, Zhou L. Effects of mitomycin C on the expression of

proliferating cell nuclear antigen after filtering surgery in rabbits. Graefes Arch Clin Exp Ophthalmol


Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 2005;118:3759-3768.

Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival Bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology 2008;115:2141-2145 e2.

Fontana H, Nouri-Mahdavi K, Lumba J, Ralli M, Caprioli J. Trabeculectomy with mitomycin C:

outcomes and risk factors for failure in phakic openangle glaucoma. Ophthalmology 2006;113:930-936.

Singh RP, Goldberg I, Mohsin M. The efficacy and safety of intraoperative and/or postoperative 5-

fluorouracil in trabeculectomy and phacotrabeculectomy. Clin Experiment Ophthalmol

;29:296-302. 13. Azuara-Blanco A, Katz LJ. Dysfunctional filtering

blebs. Surv Ophthalmol 1998;43:93-126.

Cantor LB, Mantravadi A, WuDunn D, Swamynathan K, Cortes A. Morphologic classification of filtering blebs after glaucoma filtration surgery: the Indiana Bleb Appearance Grading Scale. J Glaucoma 2003;12:266-271.

Wells AP, Ashraff NN, Hall RC, Purdie G. Comparison of two clinical Bleb grading systems. Ophthalmology 2006;113:77-83.

Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol


Khaw P, Grehn F, Overton B, Wilson R, Vogel R, Smith Z. A phase III study of subconjunctival human antitransforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 2007;114:1822-1830.

Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 2003;44:3394-3401.

Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal Bevacizumab (Avastin). Ophthalmology 2007;114:855-859.

Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal Bevacizumab for filtering surgery. Ophthalmic Res 2007;39:121-122.

Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998;141:1659-1673.

Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N ,et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995;92:365- 371.

Memarzadeh F, Varma R, Lin LT, Parikh J G , Dustin L, Alcaraz A et al. Postoperative use of Bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 2009;50:3233- 3237.

Kahook MY, Schuman JS, Noecker RJ. Intravitreal Bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006;37:144-146.

Yazdani S, Hendi K, Pakravan M. Intravitreal Bevacizumab (Avastin) injection for neovascular

glaucoma. J Glaucoma 2007;16:437-439.

Cheung JC, Wright MM, Murali S, Pederson JE. Intermediate-term outcome of variable dose

mitomycin C filtering surgery. Ophthalmology 1997;104:143-149

Cillino S, Di Pace F, Casuccio A, Cillino G, Lodato G. Deep sclerectomy versus trabeculectomy with lowdosage mitomycin C: four-year follow-up. Ophthalmologica 2008;222:81-87.

Perkins TW, Gangnon R, Ladd W, Kaufman PL, Heatley GA. Trabeculectomy with mitomycin C:

intermediate-term results. J Glaucoma 1998;7:230-236.

Grewel J, Rajeav D, Brar G. Bleb charactristic with subconj Bevacizumab and mitomycin C augmented Trabeculectomy. XXIV Congress of ESCRT Stochholm 2007.9 Septamber.Poster.

Chalam KV, Gupta SK, Grover S, Brar VS, Agarwal S. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol 2008;18:255-262.

Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Intracameral Bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142:158-160.


  • There are currently no refbacks.

Home  Journals  Conferences  Store  Services  About Us  Contact Us